Top

Published in:

Open Access 01-12-2013 | Review

ADAMTS proteoglycanases in the physiological and pathological central nervous system

Authors: Sighild Lemarchant, Mathilde Pruvost, Joan Montaner, Evelyne Emery, Denis Vivien, Katja Kanninen, Jari Koistinaho

Published in: Journal of Neuroinflammation | Issue 1/2013

Abstract

ADAMTS-1, -4, -5 and -9 belong to ‘a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)’ family and more precisely to the proteoglycanases subgroup based on their common ability to degrade chondroitin sulfate proteoglycans. They have been extensively investigated for their involvement in inflammation-induced osteoarthritis, and a growing body of evidence indicates that they may be of key importance in the physiological and pathological central nervous system (CNS). In this review, we discuss the deregulated expression of ADAMTS proteoglycanases during acute CNS injuries, such as stroke and spinal cord injury. Then, we provide new insights on ADAMTS proteoglycanases mediating synaptic plasticity, neurorepair, angiogenesis and inflammation mechanisms. Altogether, this review allows us to propose that ADAMTS proteoglycanases may be original therapeutic targets for CNS injuries.

Tang BL: ADAMTS: a novel family of extracellular matrix proteases. Int J Biochem Cell Biol 2001, 33:33–44.CrossRefPubMed

Apte SS: A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: the ADAMTS family. Int J Biochem Cell Biol 2004, 36:981–985.CrossRefPubMed

Flannery CR, Zeng W, Corcoran C, Collins-Racie LA, Chockalingam PS, Hebert T, Mackie SA, McDonagh T, Crawford TK, Tomkinson KN, LaVallie ER, Morris EA: Autocatalytic cleavage of ADAMTS-4 (Aggrecanase-1) reveals multiple glycosaminoglycan-binding sites. J Biol Chem 2002, 277:42775–42780.CrossRefPubMed

Lin EA, Liu CJ: The role of ADAMTSs in arthritis. Protein Cell 2010, 1:33–47.CrossRefPubMedPubMedCentral

Wang P, Tortorella M, England K, Malfait AM, Thomas G, Arner EC, Pei D: Proprotein convertase furin interacts with and cleaves pro-ADAMTS4 (Aggrecanase-1) in the trans-Golgi network. J Biol Chem 2004, 279:15434–15440.CrossRefPubMed

Tortorella M, Pratta M, Liu RQ, Abbaszade I, Ross H, Burn T, Arner E: The thrombospondin motif of aggrecanase-1 (ADAMTS-4) is critical for aggrecan substrate recognition and cleavage. J Biol Chem 2000, 275:25791–25797.CrossRefPubMed

Rodriguez-Manzaneque JC, Milchanowski AB, Dufour EK, Leduc R, Iruela-Arispe ML: Characterization of METH-1/ADAMTS1 processing reveals two distinct active forms. J Biol Chem 2000, 275:33471–33479.CrossRefPubMed

Gao G, Westling J, Thompson VP, Howell TD, Gottschall PE, Sandy JD: Activation of the proteolytic activity of ADAMTS4 (aggrecanase-1) by C-terminal truncation. J Biol Chem 2002, 277:11034–11041.CrossRefPubMed

Majerus EM, Zheng X, Tuley EA, Sadler JE: Cleavage of the ADAMTS13 propeptide is not required for protease activity. J Biol Chem 2003, 278:46643–46648.CrossRefPubMed

10.

Gao G, Plaas A, Thompson VP, Jin S, Zuo F, Sandy JD: ADAMTS4 (aggrecanase-1) activation on the cell surface involves C-terminal cleavage by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase and binding of the activated proteinase to chondroitin sulfate and heparan sulfate on syndecan-1. J Biol Chem 2004, 279:10042–10051.CrossRefPubMed

11.

Porter S, Clark IM, Kevorkian L, Edwards DR: The ADAMTS metalloproteinases. Biochem J 2005, 386:15–27.CrossRefPubMedPubMedCentral

12.

Llamazares M, Cal S, Quesada V, López-Otín C: Identification and characterization of ADAMTS-20 defines a novel subfamily of metalloproteinases-disintegrins with multiple thrombospondin-1 repeats and a unique GON domain. J Biol Chem 2003, 278:13382–13389.CrossRefPubMed

13.

Nicholson AC, Malik SB, Logsdon JM, Van Meir EG: Functional evolution of ADAMTS genes: evidence from analyses of phylogeny and gene organization. BMC Evol Biol 2005, 5:11.CrossRefPubMedPubMedCentral

14.

Stanton H, Melrose J, Little CB, Fosang AJ: Proteoglycan degradation by the ADAMTS family of proteinases. Biochim Biophys Acta 2011, 1812:1616–1629.CrossRefPubMed

15.

Rolls A, Shechter R, Schwartz M: The bright side of the glial scar in CNS repair. Nat Rev Neurosci 2009, 10:235–241.CrossRefPubMed

16.

Yuan W, Matthews RT, Sandy JD, Gottschall PE: Association between protease-specific proteolytic cleavage of brevican and synaptic loss in the dentate gyrus of kainate-treated rats. Neuroscience 2002, 114:1091–1101.CrossRefPubMed

17.

Miguel RF, Pollak A, Lubec G: Metalloproteinase ADAMTS-1 but not ADAMTS-5 is manifold overexpressed in neurodegenerative disorders as Down syndrome, Alzheimer’s and Pick’s disease. Brain Res Mol Brain Res 2005, 133:1–5.CrossRefPubMed

18.

Jungers KA, Le Goff C, Somerville RP, Apte SS: Adamts9 is widely expressed during mouse embryo development. Gene Expr Patterns 2005, 5:609–617.CrossRefPubMed

19.

Howell MD, Torres-Collado AX, Iruela-Arispe ML, Gottschall PE: Selective decline of synaptic protein levels in the frontal cortex of female mice deficient in the extracellular metalloproteinase ADAMTS1. PLoS One 2012, 7:e47226.CrossRefPubMedPubMedCentral

20.

Krstic D, Rodriguez M, Knuesel I: Regulated proteolytic processing of Reelin through interplay of tissue plasminogen activator (tPA), ADAMTS-4, ADAMTS-5, and their modulators. PLoS One 2012, 7:e47793.CrossRefPubMedPubMedCentral

21.

Cross AK, Haddock G, Surr J, Plumb J, Bunning RA, Buttle DJ, Woodroofe MN: Differential expression of ADAMTS-1, -4, -5 and TIMP-3 in rat spinal cord at different stages of acute experimental autoimmune encephalomyelitis. J Autoimmun 2006, 26:16–23.CrossRefPubMed

22.

Haddock G, Cross AK, Plumb J, Surr J, Buttle DJ, Bunning RA, Woodroofe MN: Expression of ADAMTS-1, -4, -5 and TIMP-3 in normal and multiple sclerosis CNS white matter. Mult Scler 2006, 12:386–396.CrossRefPubMed

23.

Cross AK, Haddock G, Stock CJ, Allan S, Surr J, Bunning RA, Buttle DJ, Woodroofe MN: ADAMTS-1 and -4 are up-regulated following transient middle cerebral artery occlusion in the rat and their expression is modulated by TNF in cultured astrocytes. Brain Res 2006, 1088:19–30.CrossRefPubMed

24.

Tauchi R, Imagama S, Natori T, Ohgomori T, Muramoto A, Shinjo R, Matsuyama Y, Ishiguro N, Kadomatsu K: The endogenous proteoglycan-degrading enzyme ADAMTS-4 promotes functional recovery after spinal cord injury. J Neuroinflammation 2012, 9:53.CrossRefPubMedPubMedCentral

25.

Hamel MG, Mayer J, Gottschall PE: Altered production and proteolytic processing of brevican by transforming growth factor beta in cultured astrocytes. J Neurochem 2005, 93:1533–1541.CrossRefPubMed

26.

Hamel MG, Ajmo JM, Leonardo CC, Zuo F, Sandy JD, Gottschall PE: Multimodal signaling by the ADAMTSs (a disintegrin and metalloproteinase with thrombospondin motifs) promotes neurite extension. Exp Neurol 2008, 210:428–440.CrossRefPubMed

27.

Bonneh-Barkay D, Wiley CA: Brain extracellular matrix in neurodegeneration. Brain Pathol 2009, 19:573–585.CrossRefPubMed

28.

Tian Y, Yuan W, Fujita N, Wang J, Wang H, Shapiro IM, Risbud MV: Inflammatory cytokines associated with degenerative disc disease control aggrecanase-1 (ADAMTS-4) expression in nucleus pulposus cells through MAPK and NF-κB. Am J Pathol 2013, 182:2310–2321.CrossRefPubMedPubMedCentral

29.

Huh JE, Seo BK, Park YC, Kim JI, Lee JD, Choi DY, Baek YH, Park DS: WIN-34B, a new herbal medicine, inhibits the inflammatory response by inactivating IκB-α phosphorylation and mitogen activated protein kinase pathways in fibroblast-like synoviocytes. J Ethnopharmacol 2012, 143:779–786.CrossRefPubMed

30.

Mimata Y, Kamataki A, Oikawa S, Murakami K, Uzuki M, Shimamura T, Sawai T: Interleukin-6 upregulates expression of ADAMTS-4 in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Int J Rheum Dis 2012, 15:36–44.CrossRefPubMed

31.

Séguin CA, Bojarski M, Pilliar RM, Roughley PJ, Kandel RA: Differential regulation of matrix degrading enzymes in a TNFalpha-induced model of nucleus pulposus tissue degeneration. Matrix Biol 2006, 25:409–418.CrossRefPubMed

32.

Reid MJ, Cross AK, Haddock G, Allan SM, Stock CJ, Woodroofe MN, Buttle DJ, Bunning RA: ADAMTS-9 expression is up-regulated following transient middle cerebral artery occlusion (tMCAo) in the rat. Neurosci Lett 2009, 452:252–257.CrossRefPubMed

33.

Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, Barres BA: Genomic analysis of reactive astrogliosis. J Neurosci 2012, 32:6391–6410.CrossRefPubMedPubMedCentral

34.

Demircan K, Yonezawa T, Takigawa T, Topcu V, Erdogan S, Ucar F, Armutcu F, Yigitoglu MR, Ninomiya Y, Hirohata S: ADAMTS1, ADAMTS5, ADAMTS9 and aggrecanase-generated proteoglycan fragments are induced following spinal cord injury in mouse. Neurosci Lett 2013, 544:25–30.CrossRefPubMed

35.

Sasaki M, Seo-Kiryu S, Kato R, Kita S, Kiyama H: A disintegrin and metalloprotease with thrombospondin type1 motifs (ADAMTS-1) and IL-1 receptor type 1 mRNAs are simultaneously induced in nerve injured motor neurons. Brain Res Mol Brain Res 2001, 89:158–163.CrossRefPubMed

36.

Ashlin TG, Kwan AP, Ramji DP: Regulation of ADAMTS-1, -4 and -5 expression in human macrophages: differential regulation by key cytokines implicated in atherosclerosis and novel synergism between TL1A and IL-17. Cytokine 2013, 64:234–242.CrossRefPubMedPubMedCentral

37.

Wågsäter D, Björk H, Zhu C, Björkegren J, Valen G, Hamsten A, Eriksson P: ADAMTS-4 and -8 are inflammatory regulated enzymes expressed in macrophage-rich areas of human atherosclerotic plaques. Atherosclerosis 2008, 196:514–522.CrossRefPubMed

38.

Ren P, Zhang L, Xu G, Palmero LC, Albini PT, Coselli JS, Shen YH, LeMaire SA: ADAMTS-1 and ADAMTS-4 levels are elevated in thoracic aortic aneurysms and dissections. Ann Thorac Surg 2013, 95:570–577.CrossRefPubMed

39.

Westling J, Gottschall PE, Thompson VP, Cockburn A, Perides G, Zimmermann DR, Sandy JD: ADAMTS4 (aggrecanase-1) cleaves human brain versican V2 at Glu405-Gln406 to generate glial hyaluronate binding protein. Biochem J 2004, 377:787–795.CrossRefPubMedPubMedCentral

40.

Didangelos A, Mayr U, Monaco C, Mayr M: Novel role of ADAMTS-5 protein in proteoglycan turnover and lipoprotein retention in atherosclerosis. J Biol Chem 2012, 287:19341–19345.CrossRefPubMedPubMedCentral

41.

Diamantis I, Lüthi M, Hösli M, Reichen J: Cloning of the rat ADAMTS-1 gene and its down regulation in endothelial cells in cirrhotic rats. Liver 2000, 20:165–172.CrossRefPubMed

42.

Hsu YP, Staton CA, Cross N, Buttle DJ: Anti-angiogenic properties of ADAMTS-4 in vitro. Int J Exp Pathol 2012, 93:70–77.CrossRefPubMedPubMedCentral

43.

Basile DP, Fredrich K, Chelladurai B, Leonard EC, Parrish AR: Renal ischemia reperfusion inhibits VEGF expression and induces ADAMTS-1, a novel VEGF inhibitor. Am J Physiol Renal Physiol 2008, 294:F928-F936.CrossRefPubMed

44.

Lo PH, Lung HL, Cheung AK, Apte SS, Chan KW, Kwong FM, Ko JM, Cheng Y, Law S, Srivastava G, Zabarovsky ER, Tsao SW, Tang JC, Stanbridge EJ, Lung ML: Extracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesis. Cancer Res 2010, 70:5567–5576.CrossRefPubMedPubMedCentral

45.

Kumar S, Sharghi-Namini S, Rao N, Ge R: ADAMTS5 functions as an anti-angiogenic and anti-tumorigenic protein independent of its proteoglycanase activity. Am J Pathol 2012, 181:1056–1068.CrossRefPubMed

46.

Lafuente JV, Ortuzar N, Bengoetxea H, Bulnes S, Argandoña EG: Vascular endothelial growth factor and other angioglioneurins: key molecules in brain development and restoration. Int Rev Neurobiol 2012, 102:317–346.CrossRefPubMed

47.

Lau LW, Keough MB, Haylock-Jacobs S, Cua R, Döring A, Sloka S, Stirling DP, Rivest S, Yong VW: Chondroitin sulfate proteoglycans in demyelinated lesions impair remyelination. Ann Neurol 2012, 72:419–432.CrossRefPubMed

48.

Siebert JR, Stelzner DJ, Osterhout DJ: Chondroitinase treatment following spinal contusion injury increases migration of oligodendrocyte progenitor cells. Exp Neurol 2011, 231:19–29.CrossRefPubMed

49.

Hobohm C, Günther A, Grosche J, Rossner S, Schneider D, Brückner G: Decomposition and long-lasting downregulation of extracellular matrix in perineuronal nets induced by focal cerebral ischemia in rats. J Neurosci Res 2005, 80:539–548.CrossRefPubMed

50.

Gherardini L, Gennaro M, Pizzorusso T: Perilesional treatment with chondroitinase ABC and motor training promote functional recovery after stroke in rats. Cereb Cortex 2013. epub ahead of print

51.

Hill JJ, Jin K, Mao XO, Xie L, Greenberg DA: Intracerebral chondroitinase ABC and heparan sulfate proteoglycan glypican improve outcome from chronic stroke in rats. Proc Natl Acad Sci U S A 2012, 109:9155–9160.CrossRefPubMedPubMedCentral

52.

Soleman S, Yip PK, Duricki DA, Moon LD: Delayed treatment with chondroitinase ABC promotes sensorimotor recovery and plasticity after stroke in aged rats. Brain 2012, 135:1210–1223.CrossRefPubMed

53.

Zuo J, Neubauer D, Dyess K, Ferguson TA, Muir D: Degradation of chondroitin sulfate proteoglycan enhances the neurite-promoting potential of spinal cord tissue. Exp Neurol 1998, 154:654–662.CrossRefPubMed

54.

Zuo J, Neubauer D, Graham J, Krekoski CA, Ferguson TA, Muir D: Regeneration of axons after nerve transection repair is enhanced by degradation of chondroitin sulfate proteoglycan. Exp Neurol 2002, 176:221–228.CrossRefPubMed

55.

Bradbury EJ, Carter LM: Manipulating the glial scar: chondroitinase ABC as a therapy for spinal cord injury. Brain Res Bull 2011, 84:306–316.CrossRefPubMed

56.

Bradbury EJ, Moon LD, Popat RJ, King VR, Bennett GS, Patel PN, Fawcett JW, McMahon SB: Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature 2002, 416:636–640.CrossRefPubMed

57.

Tom VJ, Sandrow-Feinberg HR, Miller K, Santi L, Connors T, Lemay MA, Houlé JD: Combining peripheral nerve grafts and chondroitinase promotes functional axonal regeneration in the chronically injured spinal cord. J Neurosci 2009, 29:14881–14890.CrossRefPubMedPubMedCentral

58.

Cua RC, Lau LW, Keough MB, Midha R, Apte SS, Yong VW: Overcoming neurite-inhibitory chondroitin sulfate proteoglycans in the astrocyte matrix. Glia 2013, 61:972–984.CrossRefPubMed

59.

Siebert JR, Osterhout DJ: The inhibitory effects of chondroitin sulfate proteoglycans on oligodendrocytes. J Neurochem 2011, 119:176–188.CrossRefPubMed

60.

Sasaki M, Lankford KL, Radtke C, Honmou O, Kocsis JD: Remyelination after olfactory ensheathing cell transplantation into diverse demyelinating environments. Exp Neurol 2011, 229:88–98.CrossRefPubMed

61.

Mayeur A, Duclos C, Honoré A, Gauberti M, Drouot L, Do Rego JC, Bon-Mardion N, Jean L, Vérin E, Emery E, et al.: Potential of olfactory ensheathing cells from different sources for spinal cord repair. PLoS One 2013, 8:e62860.CrossRefPubMedPubMedCentral

62.

Guérout N, Derambure C, Drouot L, Bon-Mardion N, Duclos C, Boyer O, Marie JP: Comparative gene expression profiling of olfactory ensheathing cells from olfactory bulb and olfactory mucosa. Glia 2010, 58:1570–1580.PubMed

63.

Lim NH, Kashiwagi M, Visse R, Jones J, Enghild JJ, Brew K, Nagase H: Reactive-site mutants of N-TIMP-3 that selectively inhibit ADAMTS-4 and ADAMTS-5: biological and structural implications. Biochem J 2010, 431:113–122.CrossRefPubMedPubMedCentral

64.

Daneman R: The blood–brain barrier in health and disease. Ann Neurol 2012, 72:648–672.CrossRefPubMed

65.

Pardeshi CV, Belgamwar VS: Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood–brain barrier: an excellent platform for brain targeting. Expert Opin Drug Deliv 2013, 10:957–972.CrossRefPubMed

Title: ADAMTS proteoglycanases in the physiological and pathological central nervous system
Authors: Sighild Lemarchant
Mathilde Pruvost
Joan Montaner
Evelyne Emery
Denis Vivien
Katja Kanninen
Jari Koistinaho
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Journal of Neuroinflammation / Issue 1/2013
Electronic ISSN: 1742-2094
DOI: https://doi.org/10.1186/1742-2094-10-133

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

ADAMTS proteoglycanases in the physiological and pathological central nervous system

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Intravenous immunoglobulin and Alzheimer’s disease: what now?

Activation of microglia induces symptoms of Parkinson’s disease in wild-type, but not in IL-1 knockout mice

Cognitive and cerebrovascular improvements following kinin B1 receptor blockade in Alzheimer’s disease mice

Corticosteroid therapy in a patient with cerebral amyloid angiopathy-related inflammation

Amelioration of autoimmune neuroinflammation by the fusion molecule Fn14·TRAIL

Increased interleukin-17 in the cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease: a case-control study of rapidly progressive dementia